Anand, Dr, et al. “Cardiometabolic Effectiveness and Safety of SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk: A Prospective Observational Study”. Adolescência E Saúde, Sept. 2026, pp. 454-8, doi:10.67440/ahj.vi.2007.